In this episode of Clinical Lab Chat, CLP’s Director of Business Intelligence, Chris Wolski, discusses the how and why of making precise clinical diagnosis of neurodegenerative diseases with Russ Lebovitz, MD, PhD, co-founder and CEO of Amprion.

Among the topics they discuss:

• The critical importance of making accurate diagnoses of neurodegenerative diseases
• Why alpha-synuclein is an accurate biomarker for a number of degenerative diseases, including Alzheimer’s
• How adding neurodegenerative testing to the routine diagnostic menu would benefit patients and their caregivers
• Why we’re entering a neurological healthcare “golden age”